53 related articles for article (PubMed ID: 9755618)
1. [PET as a tool in pharmacologic development].
Bergström M; Hartvig P; Långström B
Nord Med; 1998 Sep; 113(7):226-9. PubMed ID: 9755618
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography for use in microdosing studies.
Wagner CC; Müller M; Lappin G; Langer O
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):104-10. PubMed ID: 18175273
[TBL] [Abstract][Full Text] [Related]
4. Application of PET/CT in the development of novel anticancer drugs.
Boss DS; Olmos RV; Sinaasappel M; Beijnen JH; Schellens JH
Oncologist; 2008 Jan; 13(1):25-38. PubMed ID: 18245010
[TBL] [Abstract][Full Text] [Related]
5. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease.
Bauer M; Langer O; Dal-Bianco P; Karch R; Brunner M; Abrahim A; Lanzenberger R; Hofmann A; Joukhadar C; Carminati P; Ghirardi O; Piovesan P; Forloni G; Corrado ME; Lods N; Dudczak R; Auff E; Kletter K; Müller M
Clin Pharmacol Ther; 2006 Sep; 80(3):216-27. PubMed ID: 16952488
[TBL] [Abstract][Full Text] [Related]
6. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography.
Schottelius M; Poethko T; Herz M; Reubi JC; Kessler H; Schwaiger M; Wester HJ
Clin Cancer Res; 2004 Jun; 10(11):3593-606. PubMed ID: 15173065
[TBL] [Abstract][Full Text] [Related]
7. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922.
Bergstrom M; Monazzam A; Razifar P; Ide S; Josephsson R; Langstrom B
J Nucl Med; 2008 Jul; 49(7):1204-10. PubMed ID: 18552146
[TBL] [Abstract][Full Text] [Related]
8. Novel amphiphilic probes for [18F]-radiolabeling preformed liposomes and determination of liposomal trafficking by positron emission tomography.
Urakami T; Akai S; Katayama Y; Harada N; Tsukada H; Oku N
J Med Chem; 2007 Dec; 50(26):6454-7. PubMed ID: 18052025
[TBL] [Abstract][Full Text] [Related]
9. Ab initio computational study of positron emission tomography ligands interacting with lipid molecule for the prediction of nonspecific binding.
Rosso L; Gee AD; Gould IR
J Comput Chem; 2008 Nov; 29(14):2397-405. PubMed ID: 18442082
[TBL] [Abstract][Full Text] [Related]
10. PET and drug research and development.
Fowler JS; Volkow ND; Wang GJ; Ding YS; Dewey SL
J Nucl Med; 1999 Jul; 40(7):1154-63. PubMed ID: 10405137
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer therapy: the role of PET-CT in decision making.
Pons F; Duch J; Fuster D
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):210-23. PubMed ID: 19293769
[TBL] [Abstract][Full Text] [Related]
12. Mass effect of injected dose in small rodent imaging by SPECT and PET.
Kung MP; Kung HF
Nucl Med Biol; 2005 Oct; 32(7):673-8. PubMed ID: 16243641
[TBL] [Abstract][Full Text] [Related]
13. The role of [18F]fluoride positron emission tomography in the early detection of aseptic loosening of total knee arthroplasty.
Sterner T; Pink R; Freudenberg L; Jentzen T; Quitmann H; Bockisch A; Löer F
Int J Surg; 2007 Apr; 5(2):99-104. PubMed ID: 17448973
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography/computed tomography: the current technology and applications.
Mittra E; Quon A
Radiol Clin North Am; 2009 Jan; 47(1):147-60. PubMed ID: 19195540
[TBL] [Abstract][Full Text] [Related]
15. Using positron emission tomography to facilitate CNS drug development.
Lee CM; Farde L
Trends Pharmacol Sci; 2006 Jun; 27(6):310-6. PubMed ID: 16678917
[TBL] [Abstract][Full Text] [Related]
16. Clinical aspects of drug actions & interactions in veterinary practice.
Szabuniewicz M; Bailey EM; Wiersig DO
Vet Med Small Anim Clin; 1973 Sep; 68(9):1048 passim. PubMed ID: 4584293
[No Abstract] [Full Text] [Related]
17. [Hazards of modern therapy].
Kemper F
Z Allgemeinmed; 1970 Sep; 46(26):1275-8. PubMed ID: 5522823
[No Abstract] [Full Text] [Related]
18. [Therapeutic interactions].
Laroche C; Vigne J; Grégoire J
Cah Med; 1974 Nov; 15(13):829-39. PubMed ID: 4451866
[No Abstract] [Full Text] [Related]
19. [Discussion of a "home-pharmacy"].
Mackeprang B; Nedergaard M
Ugeskr Laeger; 1972 Sep; 134(39):2038-43. PubMed ID: 5077736
[No Abstract] [Full Text] [Related]
20. The incidence of drug-diagnostic test interferences in outpatients.
Munzenberger P; Emmanuel Sister
Am J Hosp Pharm; 1971 Oct; 28(10):786-91. PubMed ID: 5125173
[No Abstract] [Full Text] [Related]
[Next] [New Search]
